Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation In Vivo and In Vitro

Clinical Cancer Research

Volumn 17, Issue 7, 2011, Pages 1815-1827

  Sano, Daisuke ^a   Matsumoto, Fumihiko ^a   Valdecanas, David R ^a   Zhao, Mei ^a   Molkentine, David P ^a   Takahashi, Yoko ^a   Hanna, Ehab Y ^a   Papadimitrakopoulou, Vali ^a   Heymach, John ^a   Milas, Luka ^a   Myers, Jeffrey N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; VANDETANIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; BLOOD VESSEL PARAMETERS; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL SURVIVAL; CERVICAL LYMPH NODE; CHEMORADIOTHERAPY; CHEMOSENSITIVITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DISEASE MODEL; ENDOTHELIUM CELL; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; MICROVESSEL DENSITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PIPERIDINES; QUINAZOLINES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79953314675     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2120     Document Type: Article

References (50)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Goldberg HI, Lockwood SA, Wyatt SW, Crossett LS. Trends and differentials in mortality from cancers of the oral cavity and pharynx in the United States, 1973-1987. Cancer 1994;74:565-72.
3. Sano D, Myers JN. Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metast Rev 2007;26:645-62. (Pubitemid 350115112)
4. Forastiere AA. Is there a new role for induction chemotherapy in the treatment of head and neck cancer? J Natl Cancer Inst 2004; 96:1647-9.
5. Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-8.
6. Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-804. (Pubitemid 28277960)
7. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-8. (Pubitemid 37464533)
8. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-44.
9. Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:3562-7.
10. Rabbani A, Hinerman RW, Schmalfuss IM, Amdur RJ, Morris CG, Peters KR, et al. Radiotherapy and concomitant intraarterial cisplatin (RADPLAT) for advanced squamous cell carcinomas of the head and neck. Am J Clin Oncol 2007;30:283-6. (Pubitemid 46884149)
11. West CM, Davidson SE, Roberts SA, Hunter RD. Intrinsic radiosensitivity and prediction of patient response to radiotherapy for carcinoma of the cervix. Br J Cancer 1993;68:819-23. (Pubitemid 23301293)
12. Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K, et al. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 1999;10:2493-506. (Pubitemid 29393505)
13. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-65. (Pubitemid 32197693)
14. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002;8:885-92. (Pubitemid 34742122)
15. Liang K, Ang KK, Milas L, Hunter N, Fan Z. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003;57:246-54. (Pubitemid 36959763)
16. Shin DM, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994;54:3153-9. (Pubitemid 24208920)
17. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-6. (Pubitemid 36025259)
18. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-8.
19. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62. (Pubitemid 40093472)
20. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9. (Pubitemid 32937367)
21. Flaig TW, Su LJ, McCoach C, Li Y, Raben D, Varella-Garcia M, et al. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. BJU Int 2009;103:1729-37.
22. Sano D, Fooshee DR, Zhao M, Andrews GA, Frederick MJ, Galer C, et al. Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model. Head Neck 2010 Jul 13. [Epub ahead of print].
23. Zhou G, Xie TX, Zhao M, Jasser SA, Younes MN, Sano D, et al. Reciprocal negative regulation between S100A7/psoriasin and beta-catenin signaling plays an important role in tumor progression of squamous cell carcinoma of oral cavity. Oncogene 2008;27: 3527-38. (Pubitemid 351793795)
24. Yigitbasi OG, Younes MN, Doan D, Jasser SA, Schiff BA, Bucana CD, et al. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res 2004;64:7977-84. (Pubitemid 39446932)
25. Sano D, Myers JN. Xenograft models of head and neck cancers. Head Neck Oncol 2009;1:32.
26. Myers JN, Holsinger FC, Jasser SA, Bekele BN, Fidler IJ. An orthotopic nude mouse model of oral tongue squamous cell carcinoma. Clin Cancer Res 2002;8:293-8. (Pubitemid 34101491)
27. McNally LR, Rosenthal EL, Zhang W, Buchsbaum DJ. Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation. Cancer Gene Ther 2009;16:246-55.
28. Shibuya K, Komaki R, Shintani T, Itasaka S, Ryan A, Jürgensmeier JM, et al. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007;69:1534-43. (Pubitemid 350116420)
29. Milas L, Fujii T, Hunter N, Elshaikh M, Mason K, Plunkett W, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 1999;59:107-14. (Pubitemid 29062965)
30. Sano D, Choi S, Milas ZL, Zhou G, Galer CE, Su YW, et al. The effect of combination anti-endothelial growth factor receptor and anti-vascular endothelial growth factor receptor 2 targeted therapy on lymph node metastasis: a study in an orthotopic nude mouse model of squamous cell carcinoma of the oral tongue. Arch Otolaryngol Head Neck Surg 2009;135:411-20.
31. Ang KK, Harris J, Garden AS, Trotti A, Jones CU, Carrascosa L, et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol 2005;23:3008-15. (Pubitemid 46224121)
32. Garden AS, Asper JA, Morrison WH, Schechter NR, Glisson BS, Kies MS, et al. Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma?Cancer 2004;100:1171-8.
33. Schuurbiers OC, Kaanders JH, Van Der Heijden HF, Dekhuijzen RP, Oyen WJ, Bussink J. The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol 2009;4:761-7.
34. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78. (Pubitemid 43209104)
35. O'Reilly MS. Radiation combined with antiangiogenic and antivascular agents. Semin Radiat Oncol 2006;16:45-50.
36. Kato T, Duffey DC, Ondrey FG, Dong G, Chen Z, Cook JA, et al. Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-kappaB. Head Neck 2000;22:748-59.
37. Tanaka T, Yukawa K, Umesaki N. Radiation enhances cisplatin-sensitivity in human cervical squamous cancer cells in vitro. Eur J Gynaecol Oncol 2005;26:431-3. (Pubitemid 41139475)
38. Douple EB. Platinum-radiation interactions. NCI Monogr 1988:315-9.
39. Brazelle WD, Shi W, Siemann DW. VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy. Int J Radiat Oncol Biol Phys 2006;65:836-41. (Pubitemid 43795843)
40. Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, et al. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 2007;6:471-83. (Pubitemid 46332449)
41. Gustafson DL, Frederick B, Merz AL, Raben D. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. Cancer Chemother Pharmacol 2008;61:179-88. (Pubitemid 350160317)
42. Bianco C, Giovannetti E, Ciardiello F, Mey V, Nannizzi S, Tortora G, et al. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Clin Cancer Res 2006;12:7099-107. (Pubitemid 44974510)
43. Wachsberger P, Burd R, Ryan A, Daskalakis C, Dicker AP. Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model. Int J Radiat Oncol Biol Phys 2009;75:854-61.
44. Ansiaux R, Dewever J, Gregoire V, Feron O, Jordan BF, Gallez B. Decrease in tumor cell oxygen consumption after treatment with vandetanib (ZACTIMA; ZD6474) and its effect on response to radiotherapy. Radiat Res 2009;172:584-91.
45. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003;300:1155-9. (Pubitemid 36583102)
46. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-55.
47. Chen C, Kane M, Song J, Campana J, Raben A, Hu K, et al. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol 2007;25:4880-6. (Pubitemid 350220417)
48. Kuhnt T, Sandner A, Wendt T, Engenhart-Cabillic R, Lammering G, Flentje M, et al. Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Ann Oncol ;21:2284-9.
49. Rivera F, Garcia-Castano A, Vega N, Vega-Villegas ME, Gutierrez-Sanz L. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. Expert Rev Anticancer Ther 2009;9:1421-8.
50. Papadimitrakopoulou V, Frank SJ, Blumenschein GR, et al. Phase I evaluation of vandetanib with radiation therapy (RT) ± cisplatin in previously untreated advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2009;27:abstr 6016.